Please Wait
Applying Filters...
menu
    • menu
    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    BRN 5547136

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 4,889Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Inhibrx Report Positive Ozekibart Data, Shares Cancer Updates
    Inhibrx Report Positive Ozekibart Data, Shares Cancer Updates

    24 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/inhibrx-biosciences-reports-positive-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-provides-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion-cohorts-302593250.html

    PR NEWSWIRE
    24 Oct 2025
    Share Share
    Nuvation Bio Enrolls 1st Patient in Global Study of Safusidenib
    Nuvation Bio Enrolls 1st Patient in Global Study of Safusidenib

    23 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251023640173/en/Nuvation-Bio-Enrolls-First-Patient-in-Global-Randomized-Study-of-Safusidenib-for-Maintenance-Treatment-of-High-Grade-IDH1-Mutant-Glioma

    BUSINESSWIRE
    23 Oct 2025
    Share Share
    FDA Grants NeuroNOS Orphan Drug Status for Glioblastoma in Adults
    FDA Grants NeuroNOS Orphan Drug Status for Glioblastoma in Adults

    08 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/08/3146057/0/en/NeuroNOS-Granted-FDA-Orphan-Drug-Designation-for-Glioblastoma-the-Most-Common-and-Deadliest-Primary-Malignant-Brain-Cancer-in-Adults.html

    GLOBENEWSWIRE
    08 Sep 2025
    Share Share
    Product Launch Amitzo® 100 mg Lyophilized Powder for Injection
    Product Launch Amitzo® 100 mg Lyophilized Powder for Injection

    10 Aug 2025

    // PRESS RELEASE

    https://www.nanoalvand.com/index.php/en/blog-en/10-releases/207-temozolomide-release

    PRESS RELEASE
    10 Aug 2025
    Share Share
    Sun Pharma is on FDA Import Alert List with Recent update
    Sun Pharma is on FDA Import Alert List with Recent update

    12 May 2025

    // FDA

    https://www.accessdata.fda.gov/cms_ia/importalert_189.html

    FDA
    12 May 2025
    Share Share
    Allarity's Ph2 Stenoparib Lung Cancer Trial Fully Funded By VA
    Allarity's Ph2 Stenoparib Lung Cancer Trial Fully Funded By VA

    06 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/06/3038114/0/en/Allarity-Therapeutics-Announces-Phase-2-Trial-of-Stenoparib-in-Combination-with-Temozolomide-for-Recurrent-Small-Cell-Lung-Cancer-Fully-Funded-by-the-US-Veterans-Administration.html

    GLOBENEWSWIRE
    06 Mar 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.